UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  March 25, 2008,

 

Acorda Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-50513

 

13-3831168

(State or other jurisdiction

 

(Commission

 

(I.R.S. Employer

of incorporation)

 

File Number)

 

Identification No.)

 

15 Skyline Drive, Hawthorne, NY

 

10532

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (914) 347-4300

 

Not Applicable

Former name or former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 



 

 

Item 8.01  Other Events

 

On March 25, 2008, Acorda Therapeutics, Inc. (the “Registrant”) and the National MS Society released the results of two 2008 surveys on the impact of mobility loss on people with multiple sclerosis conducted by Harris Interactive on behalf of the Registrant and the National MS Society. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this item.

 

Item 9.01  Financial Statements and Exhibits

 

99.1  Press Release dated March 25, 2008.

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Acorda Therapeutics, Inc.

 

 

April 4, 2008

By:

/s/ Jane Wasman

 

 

 

 

 

Name:

Jane Wasman

 

 

Title:

Executive Vice President, General
Counsel and Corporate Secretary

 

 

 

 

 

 

2



 

 

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated March 25, 2008

 

 

 

 

 

 

 

3